Literature DB >> 18448701

The half-life of truth: what are appropriate time horizons for research decisions?

Zoe Philips1, Karl Claxton, Stephen Palmer.   

Abstract

PURPOSE: To evaluate alternative approaches taken to estimate the population that could benefit from research and to demonstrate that explicitly modeling future change leads to more appropriate estimates of the expected value of information (EVI).
METHODS: Existing approaches to estimating the population typically focus on the time horizon for decisions, employing seemingly arbitrary estimates of the appropriate horizon. These approaches implicitly use the time horizon as a proxy for future changes in technologies, prices, and information. Different approaches to quantifying the time horizon are explored, in the context of a stylized model, to demonstrate the impact of uncertainty in this estimate on EVI. An alternative approach is developed that explicitly models future changes in technologies, prices, and information and that demonstrates the impact on EVI estimates.
RESULTS: Explicitly modeling future changes means that the EVI for the decision problem may increase or decrease over time, but the EVI for the group of parameters that can be evaluated by current research tends to decline. The finite and infinite time horizons for the decision problem represent special cases (e.g., price shock or no changes, respectively). This type of analysis can be used to inform policy decisions relating to the timing of research.
CONCLUSIONS: The value of information depends on future changes in technologies, prices, and evidence. Finite time horizons for decision problems can be seen as a proxy for the complex and uncertain process of future change. A more explicit approach to modeling these changes could provide a more appropriate basis for calculating EVI, but this raises a number of significant methodological and technical challenges.

Entities:  

Mesh:

Year:  2008        PMID: 18448701     DOI: 10.1177/0272989X07312724

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  21 in total

1.  Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

Authors:  Laura McCullagh; Cathal Walsh; Michael Barry
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

2.  Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.

Authors:  Laura McCullagh; Susanne Schmitz; Michael Barry; Cathal Walsh
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

3.  Population- versus cohort-based modelling approaches.

Authors:  Olivier Ethgen; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

4.  Exploring uncertainty in cost-effectiveness analysis.

Authors:  Karl Claxton
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  A practical guide to value of information analysis.

Authors:  Edward C F Wilson
Journal:  Pharmacoeconomics       Date:  2015-02       Impact factor: 4.981

6.  The Curve of Optimal Sample Size (COSS): A Graphical Representation of the Optimal Sample Size from a Value of Information Analysis.

Authors:  Eric Jutkowitz; Fernando Alarid-Escudero; Karen M Kuntz; Hawre Jalal
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

Review 7.  A systematic and critical review of the evolving methods and applications of value of information in academia and practice.

Authors:  Lotte Steuten; Gijs van de Wetering; Karin Groothuis-Oudshoorn; Valesca Retèl
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

8.  Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment.

Authors:  David D Kim; Gregory F Guzauskas; Caroline S Bennette; Anirban Basu; David L Veenstra; Scott D Ramsey; Josh J Carlson
Journal:  Pharmacoeconomics       Date:  2020-02       Impact factor: 4.981

9.  Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group.

Authors:  Caroline S Bennette; David L Veenstra; Anirban Basu; Laurence H Baker; Scott D Ramsey; Josh J Carlson
Journal:  Med Decis Making       Date:  2016-03-24       Impact factor: 2.583

10.  Concepts of 'personalization' in personalized medicine: implications for economic evaluation.

Authors:  Wolf Rogowski; Katherine Payne; Petra Schnell-Inderst; Andrea Manca; Ursula Rochau; Beate Jahn; Oguzhan Alagoz; Reiner Leidl; Uwe Siebert
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.